JP2018524339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524339A5 JP2018524339A5 JP2017567655A JP2017567655A JP2018524339A5 JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5 JP 2017567655 A JP2017567655 A JP 2017567655A JP 2017567655 A JP2017567655 A JP 2017567655A JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- compound
- optionally
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000004957 naphthylene group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- -1 when X b is N Chemical compound 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*(CC(C)(C1)**1I)*IN* Chemical compound C*(CC(C)(C1)**1I)*IN* 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194493A JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15174936 | 2015-07-02 | ||
| EP15174936.3 | 2015-07-02 | ||
| EP16174713 | 2016-06-16 | ||
| EP16174713.4 | 2016-06-16 | ||
| EP16174718.3 | 2016-06-16 | ||
| EP16174718 | 2016-06-16 | ||
| PCT/EP2016/065499 WO2017001660A1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194493A Division JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524339A JP2018524339A (ja) | 2018-08-30 |
| JP2018524339A5 true JP2018524339A5 (cg-RX-API-DMAC10.html) | 2019-08-08 |
| JP7099824B2 JP7099824B2 (ja) | 2022-07-12 |
Family
ID=56289523
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567655A Active JP7099824B2 (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Country Status (29)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701315VA (en) | 2014-08-28 | 2017-03-30 | Asceneuron Sa | Glycosidase inhibitors |
| WO2017001660A1 (en) * | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| JP6785252B2 (ja) | 2015-07-02 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ラクタム及びその使用方法 |
| JP7055378B2 (ja) | 2015-09-17 | 2022-04-18 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物 |
| MX381953B (es) | 2016-02-25 | 2025-03-13 | Asceneuron S A | Sales de derivados de piperazina obtenidas por adicion de acidos. |
| CN108884078A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| SMT202300273T1 (it) | 2016-03-16 | 2023-09-06 | Kura Oncology Inc | Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso |
| CA3026010A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200048267A1 (en) * | 2017-02-06 | 2020-02-13 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| MA47676A (fr) * | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| EP3684361A4 (en) * | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| RU2680972C1 (ru) * | 2018-02-13 | 2019-03-01 | Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" | Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков |
| WO2019175737A1 (en) * | 2018-03-12 | 2019-09-19 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| BR112021003022A2 (pt) | 2018-08-22 | 2021-05-11 | Asceneuron Sa | sais de adição de ácido de ácido succínico ou ácido fumárico, de ácido monossuccínico, de ácido monofumárico e de adição de ácido succínico ou sal de adição de ácido fumárico, métodos para preparar um sal de adição de ácido do ácido succínico ou ácido fumárico, para tratar uma tauopatia e para inibir uma glicosidase, e, forma de dosagem oral sólida |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CN109503631A (zh) * | 2018-12-29 | 2019-03-22 | 中国医学科学院医药生物技术研究所 | 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用 |
| EP3976031A4 (en) * | 2019-05-28 | 2023-07-12 | Shionogi & Co., Ltd | MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A MYCOBACTERIAL INFECTION CHARACTERIZED BY THE COMBINATION OF A BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE |
| KR102076958B1 (ko) | 2019-06-24 | 2020-02-13 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| CA3149868A1 (en) | 2019-09-13 | 2021-03-18 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| CN114450288A (zh) | 2019-09-30 | 2022-05-06 | 爱尔兰詹森科学公司 | 4-喹啉酮抗细菌化合物 |
| US20220372033A1 (en) | 2019-09-30 | 2022-11-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EP4081304B1 (en) | 2019-12-27 | 2024-03-06 | Tecnimede, Sociedade Técnico-Medicinal, SA | Antibacterial quinolines |
| CA3211532A1 (en) | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| AU2022236404A1 (en) | 2021-03-17 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| JP2024509997A (ja) | 2021-03-17 | 2024-03-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌化合物 |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2023275744A1 (en) | 2021-06-29 | 2023-01-05 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Heterocyclic compounds for the treatment of tuberculosis |
| CA3234515A1 (en) | 2021-10-28 | 2023-05-04 | Jose Manuel Bartolome-Nebreda | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| CN114957954B (zh) * | 2022-05-16 | 2024-08-20 | 万华化学集团股份有限公司 | 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用 |
| CN119300832A (zh) * | 2022-06-15 | 2025-01-10 | C4医药公司 | 用于靶向降解smarca2的化合物 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
| WO2025129116A1 (en) * | 2023-12-14 | 2025-06-19 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046520C (zh) | 1994-11-15 | 1999-11-17 | 法玛西雅厄普约翰美国公司 | 二环噁嗪及噻嗪噁唑烷酮抗菌剂 |
| DE69614847T2 (de) | 1995-05-11 | 2002-04-04 | Pharmacia & Upjohn Co., Kalamazoo | Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone |
| ATE463482T1 (de) | 2002-07-25 | 2010-04-15 | Janssen Pharmaceutica Nv | Chinolinderivate und deren verwendung als mycobakterielle inhibitoren |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| CN101631786A (zh) | 2006-12-20 | 2010-01-20 | 先灵公司 | 新颖的jnk抑制剂 |
| CL2008001631A1 (es) * | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| JP5613656B2 (ja) | 2008-03-26 | 2014-10-29 | グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント | 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール |
| US8658350B2 (en) | 2008-09-22 | 2014-02-25 | Oregon Health & Science University | Methods for detecting Mycobacterium tuberculosis disease |
| AU2009334997A1 (en) | 2008-12-30 | 2011-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as Raf kinase inhibitors |
| BR112012010752B1 (pt) | 2009-11-05 | 2021-07-20 | University Of Notre Dame Du Lac | Compostos imidazo[1,2-a]piridina |
| CN102869661B (zh) | 2010-03-18 | 2015-08-05 | 韩国巴斯德研究所 | 抗感染化合物 |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| US20150011508A1 (en) | 2011-09-01 | 2015-01-08 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| AU2012302042B2 (en) | 2011-09-01 | 2016-03-31 | Novartis Ag | Compounds and compositions as c-kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| SG11201405056UA (en) * | 2012-03-02 | 2014-09-26 | Genentech Inc | Amido spirocyclic amide and sulfonamide derivatives |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| BR112015001201B1 (pt) * | 2012-07-18 | 2022-02-22 | University Of Notre Dame Du Lac | Compostos anti-infecciosos 5,5-heteroaromáticos e composição |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| HUE056198T2 (hu) * | 2013-08-02 | 2022-02-28 | Pasteur Institut Korea | Fertõzés elleni vegyületek |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| JP2017533220A (ja) | 2014-11-03 | 2017-11-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 結核処置のための多剤療法 |
| WO2017001660A1 (en) | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| CA3026010A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| MX2018015657A (es) | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
| MA47676A (fr) | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
-
2016
- 2016-07-01 WO PCT/EP2016/065499 patent/WO2017001660A1/en not_active Ceased
- 2016-07-01 AU AU2016287478A patent/AU2016287478B2/en not_active Expired - Fee Related
- 2016-07-01 JP JP2017567655A patent/JP7099824B2/ja active Active
- 2016-07-01 HK HK18109081.1A patent/HK1249468A1/zh unknown
- 2016-07-01 HR HRP20220339TT patent/HRP20220339T1/hr unknown
- 2016-07-01 KR KR1020187001923A patent/KR102710552B1/ko active Active
- 2016-07-01 AU AU2016287477A patent/AU2016287477B2/en active Active
- 2016-07-01 MA MA042293A patent/MA42293A/fr unknown
- 2016-07-01 RS RS20220464A patent/RS63201B1/sr unknown
- 2016-07-01 EP EP16734637.8A patent/EP3316969B1/en active Active
- 2016-07-01 BR BR112017028318-2A patent/BR112017028318B1/pt active IP Right Grant
- 2016-07-01 CA CA2986331A patent/CA2986331A1/en not_active Abandoned
- 2016-07-01 LT LTEPPCT/EP2016/065499T patent/LT3316969T/lt unknown
- 2016-07-01 CN CN201680038659.3A patent/CN107708809A/zh active Pending
- 2016-07-01 WO PCT/EP2016/065503 patent/WO2017001661A1/en not_active Ceased
- 2016-07-01 EP EP16733105.7A patent/EP3316968A1/en not_active Ceased
- 2016-07-01 MD MDE20180478T patent/MD3316969T2/ro unknown
- 2016-07-01 SM SM20220220T patent/SMT202200220T1/it unknown
- 2016-07-01 MX MX2017016788A patent/MX386598B/es unknown
- 2016-07-01 US US15/736,524 patent/US20180155341A1/en not_active Abandoned
- 2016-07-01 ES ES16734637T patent/ES2914681T3/es active Active
- 2016-07-01 US US15/736,375 patent/US10364232B2/en active Active
- 2016-07-01 UA UAA201800904A patent/UA125171C2/uk unknown
- 2016-07-01 MX MX2017016789A patent/MX2017016789A/es unknown
- 2016-07-01 PL PL16734637T patent/PL3316969T3/pl unknown
- 2016-07-01 EA EA201890201A patent/EA201890201A1/ru unknown
- 2016-07-01 CN CN202111173668.2A patent/CN113980015A/zh active Pending
- 2016-07-01 EA EA201890204A patent/EA201890204A1/ru unknown
- 2016-07-01 EP EP22158386.7A patent/EP4074378A1/en not_active Withdrawn
- 2016-07-01 JP JP2017567289A patent/JP2018519302A/ja active Pending
- 2016-07-01 KR KR1020187002072A patent/KR20180022833A/ko not_active Ceased
- 2016-07-01 PE PE2017002738A patent/PE20180520A1/es unknown
- 2016-07-01 SI SI201631501T patent/SI3316969T1/sl unknown
- 2016-07-01 CN CN201680038644.7A patent/CN108235704B/zh active Active
- 2016-07-01 DK DK16734637.8T patent/DK3316969T3/da active
-
2017
- 2017-12-13 PH PH12017502297A patent/PH12017502297A1/en unknown
- 2017-12-13 PH PH12017502298A patent/PH12017502298A1/en unknown
- 2017-12-18 IL IL256391A patent/IL256391B/en active IP Right Grant
- 2017-12-18 IL IL256379A patent/IL256379A/en unknown
- 2017-12-20 ZA ZA2017/08692A patent/ZA201708692B/en unknown
- 2017-12-26 CO CONC2017/0013408A patent/CO2017013408A2/es unknown
- 2017-12-27 CL CL2017003404A patent/CL2017003404A1/es unknown
-
2019
- 2019-07-02 US US16/460,334 patent/US20190330189A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/848,337 patent/US11180472B2/en active Active
-
2021
- 2021-09-17 US US17/477,970 patent/US11866419B2/en active Active
- 2021-11-30 JP JP2021194493A patent/JP7516338B2/ja active Active
-
2022
- 2022-01-20 AU AU2022200385A patent/AU2022200385B2/en active Active
-
2023
- 2023-11-29 US US18/523,171 patent/US20240132470A1/en not_active Abandoned